Epilepsy Nervous System Diseases Petit mal status epilepticus
Conditions
Interventions
Participants and carers will be instructed on how to use a portable EEG system and seizure tracking diary recorded on an app. Carers will be asked to put a portable EEG headband on the patient on the
with the medication being the same that would be prescribed if they were not part of the research. After 6 weeks they will return to do the cognitive tests again and fill in a system questionnaire. If
Sponsors
Lancaster University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects eligible for inclusion in the experimental group for this study are children suspected of having absence seizures between the ages of 3- to 12-years 2. Subjects eligible for inclusion into the clinical control group are patients of a similar age, referred to Preston for a routine EEG, but not suspected of having absence seizures. If a patient is initially included in the experimental group but gets diagnosed with another condition other than absence seizures, they will be placed in the clinical control group 3. A further non-clinical control group, also age matched, will be collected at Lancaster University
Exclusion criteria
Exclusion criteria: 1. Confounding medication use: 1.1. Ritalin 1.2. Antidepressants 1.3. Neuroleptic medications 1.4. Anti-epileptics 2. Significant learning difficulties, e.g. autism 3. Neurological conditions, e.g. cerebral palsy 4. The CI may judge a participant unable to take part in the non-clinical control group if they have a diagnosis of any neurological disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seizure detection: the number of identifiable absence seizures in simultaneously collected low-density portable EEG and clinical EEG during an EEG examination; Timepoint(s): End of Data Collection | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Automatic seizure detection: the sensitivity, specificity, and false detection rate of automatic seizure detection algorithms on three datasets: EEG data collected in the clinic, NHS ‘ambulatory’ EEG data collected from the patient’s home, and low-density portable EEG data, also collected in the home. Automatic seizure detection algorithms will be compared to carers seizure diaries and clinical physiologist’s annotations 2. Patient acceptability:? patient feedback on the acceptability of both active (seizure diary) and passive (portable EEG) seizure tracking methods using a developed questionnaire that uses both open and closed questions 3. Patient adherence:? patient adherence to using the active (seizure diary) and passive (portable EEG) seizure tracking methods assessed by comparing patient’s interactions with the companion app, time spent wearing the portable EEG, and amount of usable data provided from the portable EEG 4. Cognitive assessment: cognitive assessment tasks will be conducted by all participants at baseline and after 2 weeks. Additionally, patients prescribed anti-epileptic medication for absence seizures will do these tasks at 8 weeks after the initial EEG examination. Scores from participants with absence epilepsy will be compared to controls as well as pre-and post- medication. 5. Attention and executive functioning measured by recording the accuracy and error performance on an anti-saccade eye movement task. Eye movements will be compared to controls and pre-and post- medication in absence epilepsy participants 6. Behavioral problems, measured by carer completing a Child Behaviour Checklist (CBCL) appropriate for the age of the child (1 1/2 - 5 or 6-18) 7. Verbal and non-verbal general cognitive abilities assessed using Raven’s – Educational: Coloured Progressive Matrices (CPM) or Standard Progressive Matrices (SPM) and Crichton Vocabulary Scales ( | — |
Countries
United Kingdom
Outcome results
None listed